Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluriaBernd Höppe, Craig B. Langman, Michelle A. Baum et al.|Kidney International|2021Cited by 90
LONG-TERM TRANSPLANTATION OUTCOMES IN PATIENTS WITH PRIMARY HYPEROXALURIA TYPE I: RESULTS FROM THE OXALEUROPE DATABASEElisabeth L. Metry, Jaap W. Groothoff, Sander F. Garrelfs et al.|Data Archiving and Networked Services (DANS)|2021Cited by 0